Alteration of Specific Cytokine Expression Patterns in Patients with Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2019 Mar 1

PMID 30814616

Citations 47

Authors

Kosuke Kawaguchi

Masashi Sakurai

Yasuko Yamamoto

Eiji Suzuki

Moe Tsuda

Tatsuki R Kataoka

Masahiro Hirata

Mariko Nishie

Takashi Nojiri

Motofumi Kumazoe

Kuniaki Saito

Masakazu Toi

Affiliations

Soon will be listed here.

Abstract

Systemic inflammation has been associated with aggressive tumor growth, invasion, and metastasis. Here we performed a comprehensive analysis of 26 kinds of inflammatory cytokine expression patterns among 185 patients with breast cancer and 54 healthy volunteers followed by chemometric analysis. We identified the specific cytokine expression patterns of breast cancer patients compared to healthy volunteers with (1) VEGF, IL-9, GM-CSF, IL-13, IL-4, and IFNγ, (2) IL-8, IL-10, IL-12, IL-5, IL-7, IL-1α, GCSF, IL-1β, and TNFα and (3) IL-2, Eotaxin, MIP1β, MIP1α, IL-17, and bFGF. Among the patients with breast cancer, we identified the specific cytokine signature of metastatic patients compared to non-metastatic patients. We also established a mathematical model for distinguishing patients with breast cancer from healthy volunteers and metastatic patients from non-metastatic patients. This cytokine network analysis could provide new insights into early intervention and effective therapeutic strategy for patients with breast cancer.

Citing Articles

Pro-inflammatory cytokines increase temporarily after adjuvant treatment for breast cancer in postmenopausal women: a longitudinal study.

Lindholm A, Abrahamsen M, Buch-Larsen K, Marina D, Andersson M, Helge J Breast Cancer Res. 2024; 26(1):142.

PMID: 39415181 PMC: 11481761. DOI: 10.1186/s13058-024-01898-3.

The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer.

Ishikawa E, Watanabe T, Kihara T, Kuroiwa M, Komatsu M, Urano S Breast Cancer Res Treat. 2024; 209(2):291-302.

PMID: 39402242 PMC: 11785682. DOI: 10.1007/s10549-024-07492-7.

The Role of Salivary Vascular Endothelial Growth Factor A, Cytokines, and Amino Acids in Immunomodulation and Angiogenesis in Breast Cancer.

Sarf E, Dyachenko E, Belskaya L Biomedicines. 2024; 12(6).

PMID: 38927536 PMC: 11201966. DOI: 10.3390/biomedicines12061329.

Progressive, multi-organ, and multi-layered nature of cancer cachexia.

Nakamura Y, Saldajeno D, Kawaguchi K, Kawaoka S Cancer Sci. 2024; 115(3):715-722.

PMID: 38254286 PMC: 10921013. DOI: 10.1111/cas.16078.

Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.

Saldajeno D, Kawaoka S, Masuda N, Tanaka S, Bando H, Nishimura T Br J Cancer. 2024; 130(6):1023-1035.

PMID: 38238427 PMC: 10951271. DOI: 10.1038/s41416-023-02527-0.

References

Ma Y, Aymeric L, Locher C, Mattarollo S, Delahaye N, Pereira P . Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011; 208(3):491-503. PMC: 3058575. DOI: 10.1084/jem.20100269. View

Denkert C, Loibl S, Noske A, Roller M, Muller B, Komor M . Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2009; 28(1):105-13. DOI: 10.1200/JCO.2009.23.7370. View

Chen W, Lai Y, Chen H, Guo H, Su I, Chen H . Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology. 2013; 63(2):225-33. DOI: 10.1111/his.12156. View

Lyon D, McCain N, Walter J, Schubert C . Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res. 2007; 57(1):51-8. PMC: 2234268. DOI: 10.1097/01.NNR.0000280655.58266.6c. View

Baek S, Tsai C, Chen J . Development of biomarker classifiers from high-dimensional data. Brief Bioinform. 2009; 10(5):537-46. DOI: 10.1093/bib/bbp016. View

He D, Li H, Yusuf N, Elmets C, Li J, Mountz J . IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 2010; 184(5):2281-8. PMC: 3179912. DOI: 10.4049/jimmunol.0902574. View

Baumgarten S, Frasor J . Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol. 2012; 26(3):360-71. PMC: 3286192. DOI: 10.1210/me.2011-1302. View

Leek R, Harris A . Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia. 2002; 7(2):177-89. DOI: 10.1023/a:1020304003704. View

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

10.

Pickup M, Novitskiy S, Moses H . The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013; 13(11):788-99. PMC: 4025940. DOI: 10.1038/nrc3603. View

11.

Mojsilovic S, Krstic A, Ilic V, Okic-dordevic I, Kocic J, Trivanovic D . IL-17 and FGF signaling involved in mouse mesenchymal stem cell proliferation. Cell Tissue Res. 2011; 346(3):305-16. DOI: 10.1007/s00441-011-1284-5. View

12.

Zhu X, Mulcahy L, Mohammed R, Lee A, Franks H, Kilpatrick L . IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 2008; 10(6):R95. PMC: 2656888. DOI: 10.1186/bcr2195. View

13.

Nikas J, Low W . ROC-supervised principal component analysis in connection with the diagnosis of diseases. Am J Transl Res. 2011; 3(2):180-96. PMC: 3056564. View

14.

Marotta L, Polyak K . Unraveling the complexity of basal-like breast cancer. Oncotarget. 2011; 2(8):588-9. PMC: 3248210. DOI: 10.18632/oncotarget.314. View

15.

Semesiuk N, Zhylchuk A, Bezdenezhnykh N, Lykhova A, Vorontsova A, Zhylchuk V . Disseminated tumor cells and enhanced level of some cytokines in bone marrow and peripheral blood of breast cancer patients as predictive factors of tumor progression. Exp Oncol. 2014; 35(4):295-302. View

16.

Murtaza M, Dawson S, Tsui D, Gale D, Forshew T, Piskorz A . Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497(7447):108-12. DOI: 10.1038/nature12065. View

17.

Du J, Xu K, Fang L, Qi X . Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Rep. 2012; 6(5):1099-102. DOI: 10.3892/mmr.2012.1036. View

18.

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

19.

Zhang J, Yan J, Xu J, Pang X, Chen M, Li L . Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol. 2009; 50(5):980-9. DOI: 10.1016/j.jhep.2008.12.033. View

20.

Chen X, Wan J, Liu J, Xie W, Diao X, Xu J . Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2009; 69(3):348-54. DOI: 10.1016/j.lungcan.2009.11.013. View